HERON THERAPEUTICS, INC. /DE/ (HRTX) Company Report

Heron Therapeutics reported full-year 2025 total net revenues of $154.9 million and adjusted EBITDA of $14.7 million, exceeding its previously communicated guidance range of $9 million-$13 million.
In Q4 2025, the acute care franchise showed significant growth, with ZYNRELEF net revenue increasing 48% and APONVIE growing 97% year-over-year.
The company provided 2026 guidance for net product sales between $173 million and $183 million and adjusted EBITDA between $10 million and $20 million, indicating continued profitability despite planned commercial investments.
Key strategic initiatives include the anticipated mid to late 2027 FDA approval for the ZYNRELEF prefilled syringe, the expected positive impact of the NOPAIN Act on ZYNRELEF, and the inclusion of APONVIE in new PONV consensus guidelines.
The company expressed confidence in its case regarding the Slayback litigation for CINVANTI and expects a decision before the 30-month stay.

2 days ago

Transcript

Heron Therapeutics Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported full-year 2025 net product sales of $154.9 million, representing a 7.4% increase year-over-year, and Adjusted EBITDA of $14.7 million, with a net loss of $(20.2) million.
The Acute Care franchise demonstrated significant growth, with Q4 2025 revenue increasing 57.3% year-over-year and full-year 2025 revenue up 65.1% compared to 2024.
ZYNRELEF net revenue grew 48% year-over-year in Q4 2025 to $12.5 million, supported by J-Code approval and the full commercialization of the Vial Access Needle (VAN).
APONVIE net revenue surged 97.4% year-over-year in Q4 2025 to $3.8 million, and its inclusion in the 5th consensus PONV guidelines was a key highlight.
For fiscal year 2026, the company projects Net Product Sales between $173.0 million and $183.0 million and Adjusted EBITDA between $10.0 million and $20.0 million.

2 days ago

Presentation

Heron Therapeutics Announces Q4 and Full Year 2025 Results and 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported full-year 2025 net revenue of $154.9 million, an increase of 7.4% year-over-year, and Adjusted EBITDA of $14.7 million.
The Acute Care franchise showed significant growth, with revenue increasing 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025, primarily driven by ZYNRELEF net revenue growth of 48% and APONVIE net revenue growth of 97.4% in Q4 2025.
For 2026, the company provided guidance for Net Product Sales between $173.0 million and $183.0 million and Adjusted EBITDA between $10.0 million and $20.0 million.
Key product milestones include the J-Code approval for ZYNRELEF and the full commercialization of the ZYNRELEF VAN, with FDA approval for a ZYNRELEF Prefilled Syringe market presentation anticipated in mid-to-late 2027.

2 days ago

Presentation

Heron Therapeutics Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported full-year 2025 total net revenues of approximately $155 million and adjusted EBITDA of $14.7 million, exceeding its previously communicated guidance range.
In Q4 2025, the acute care franchise showed significant year-over-year growth, with ZYNRELEF net revenue increasing 48% and APONVIE growing 97%.
For 2026, the company projects net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million.
Key strategic initiatives in 2025 included the launch of the CrossLink Ignite program, introduction of the Vial Access Needle, and new J-codes for ZYNRELEF and APONVIE, with APONVIE also included in the fifth consensus guidelines for PONV. The company anticipates potential FDA approval for the prefilled syringe presentation for ZYNRELEF in mid to late 2027.

2 days ago

Transcript

Heron Therapeutics Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported full-year 2025 total net revenues of approximately $155 million and adjusted EBITDA of $14.7 million, surpassing its previously communicated guidance range. The acute care franchise demonstrated significant momentum in Q4 2025, with ZYNRELEF net revenue growing 48% and APONVIE growing 97% year-over-year.
For 2026, the company projects net product sales between $173 million and $183 million and adjusted EBITDA between $10 million and $20 million, reflecting continued profitability despite planned increased commercial investments.
Key strategic accomplishments in 2025 included the successful completion of financing, the introduction of the Vial Access Needle (VAN), the implementation of new J-codes for ZYNRELEF and APONVIE, and APONVIE's inclusion in the 5th consensus guidelines for PONV.
Development of a prefilled syringe (PFS) presentation for ZYNRELEF is ongoing, with anticipated FDA approval in mid to late 2027 following 12 months of stability testing.

2 days ago

Transcript

Heron Therapeutics Announces Q4 and Full-Year 2025 Financial Results and 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported full-year 2025 net revenue of $154.9 million, marking a 7.4% increase from 2024, with the Acute Care franchise experiencing 65.1% year-over-year growth.
The company provided full-year 2026 guidance for net revenue between $173 million and $183 million and Adjusted EBITDA between $10 million and $20 million.
For Q4 2025, net product sales were $40.6 million, with the Acute Care franchise growing 57.3% year-over-year.
Heron Therapeutics recorded a net loss of $(20.2) million for the full year 2025 and held $46.6 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
Significant product developments include the approval of permanent, product-specific J-Codes for ZYNRELEF (effective October 1, 2025) and APONVIE, and the anticipated FDA approval for a ZYNRELEF Prefilled Syringe in mid-to-late 2027.

2 days ago

8-K

Heron Therapeutics Announces Q4 and Full-Year 2025 Financial Results and 2026 Guidance

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics reported $154.9 million in net revenue for full-year 2025, reflecting a 7.4% year-over-year increase. The Acute Care franchise, which includes ZYNRELEF and APONVIE, demonstrated 65% year-over-year net revenue growth in 2025.
For full-year 2026, the company issued net revenue guidance of $173 million to $183 million and adjusted EBITDA guidance of $10 million to $20 million.
Key product developments include the approval of permanent, product-specific J-Codes for ZYNRELEF (J0668) and APONVIE (J8502), which are expected to streamline reimbursement. Development of a Prefilled Syringe for ZYNRELEF is also progressing, with FDA approval anticipated in mid-to-late 2027.
As of December 31, 2025, Heron Therapeutics held $46.6 million in cash, cash equivalents, and short-term investments.

2 days ago

Press Release

Heron Therapeutics Announces Preliminary Unaudited Q4 and Full-Year 2025 Net Revenue

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics, Inc. announced preliminary, unaudited net revenue of approximately $40.5 million for Q4 2025 and approximately $154.9 million for full-year 2025.
ZYNRELEF® net revenue for Q4 2025 was approximately $12.5 million, representing the largest quarter-over-quarter increase within the portfolio, up approximately 35% compared to Q3 2025.
Other product net revenues for Q4 2025 included CINVANTI® at approximately $22.9 million, APONVIE® at approximately $3.8 million, and SUSTOL® at approximately $1.3 million.
These financial results are preliminary and unaudited, and actual results may differ from these estimates due to final accounting adjustments and other developments.

Jan 9, 2026, 6:08 PM

8-K

Heron Therapeutics Announces Preliminary Q4 and Full-Year 2025 Net Revenue

HRTX

Earnings

Revenue Acceleration/Inflection

Heron Therapeutics announced preliminary, unaudited net revenue of approximately $40.5 million for the fourth quarter ended December 31, 2025, and approximately $154.9 million for the full-year 2025.
For Q4 2025, ZYNRELEF® net revenue was approximately $12.5 million, APONVIE® net revenue was approximately $3.8 million, CINVANTI® net revenue was approximately $22.9 million, and SUSTOL® net revenue was approximately $1.3 million.
ZYNRELEF® delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4, up approximately 35% compared to Q3 2025.
These financial results are preliminary and unaudited, and actual results may differ as the company's financial closing and review procedures are not yet complete.

Jan 9, 2026, 2:29 PM

Press Release

Heron Therapeutics announces Q3 2025 results

HRTX

Earnings

Guidance Update

Revenue Acceleration/Inflection

Heron Therapeutics generated $38.2 million in Net Revenue for Q3 2025 and $114.3 million year-to-date.
ZYNRELEF Net Sales reached $9.3 million, a 49% year-over-year increase, and APONVIE Net Sales were $3.0 million, up 173% year-over-year in Q3 2025.
The company reported $1.5 million in Adjusted EBITDA for Q3 2025 and $9.5 million year-to-date.
Heron Therapeutics reiterated its 2025 Adjusted EBITDA guidance of $9.0 million to $13.0 million.